Discovery of (2R)‑N‑[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]‑1H‑indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide
(AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor
posted on 2020-04-28, 19:43authored byQibin Su, Erica Banks, Geraldine Bebernitz, Kirsten Bell, Cassandra F. Borenstein, Huawei Chen, Claudio E. Chuaqui, Nanhua Deng, Andrew D. Ferguson, Sameer Kawatkar, Neil P. Grimster, Linette Ruston, Paul D. Lyne, Jon A. Read, Xianyou Peng, Xiaohui Pei, Stephen Fawell, Zhanlei Tang, Scott Throner, Melissa M. Vasbinder, Haoyu Wang, Jon Winter-Holt, Richard Woessner, Allan Wu, Wenzhan Yang, Michael Zinda, Jason G. Kettle
JAK1,
JAK2, JAK3, and TYK2 belong to the JAK (Janus kinase) family.
They play critical roles in cytokine signaling. Constitutive activation
of JAK/STAT pathways is associated with a wide variety of diseases.
Particularly, pSTAT3 is observed in response to the treatment with
inhibitors of oncogenic signaling pathways such as EGFR, MAPK, and
AKT and is associated with resistance or poorer response to agents
targeting these pathways. Among the JAK family kinases, JAK1 has been
shown to be the primary driver of STAT3 phosphorylation and signaling;
therefore, selective JAK1 inhibition can be a viable means to overcome
such treatment resistances. Herein, an account of the medicinal chemistry
optimization from the promiscuous kinase screening hit 3 to the candidate drug 21 (AZD4205), a highly selective
JAK1 kinase inhibitor, is reported. Compound 21 has good
preclinical pharmacokinetics. Compound 21 displayed an
enhanced antitumor activity in combination with an approved EGFR inhibitor,
osimertinib, in a preclinical non-small-cell lung cancer (NSCLC) xenograft
NCI-H1975 model.